PDL BioPharma Inc. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
444,431.00
584,993.00
585,058.00
239,680.00
320,060.00
198,110
Cost of Goods Sold (COGS) incl. D&A
5,637.00
-
-
16,093.00
55,226.00
64,291
Gross Income
438,794.00
-
585,058.00
223,587.00
264,834.00
133,819
SG&A Expense
29,755.00
34,914.00
36,090.00
44,148.00
70,705.00
65,514
EBIT
409,039.00
550,079.00
-
179,439.00
194,129.00
68,305
Unusual Expense
-
6,143.00
2,471.00
54,211.00
349.00
118,899
Non Operating Income/Expense
1,510.00
3,768.00
5,758.00
4,909.00
10,968.00
6,829
Interest Expense
24,871.00
39,211.00
27,059.00
20,767.00
20,221.00
12,157
Pretax Income
401,876.00
501,272.00
530,138.00
109,370.00
184,527.00
55,922
Income Tax
137,346.00
179,028.00
197,343.00
45,711.00
73,826.00
12,937
Consolidated Net Income
264,530.00
322,244.00
332,795.00
63,659.00
110,701.00
68,859
Net Income
264,530.00
322,244.00
332,795.00
63,606.00
110,748.00
68,859
Net Income After Extraordinaries
264,530.00
322,244.00
332,795.00
63,606.00
110,748.00
68,859
Net Income Available to Common
264,530.00
322,244.00
332,795.00
63,606.00
110,748.00
68,859
EPS (Basic)
1.66
1.86
2.03
0.39
0.71
0.47
Basic Shares Outstanding
139,842.00
158,224.00
163,386.00
163,805.00
155,394.00
145,669
EPS (Diluted)
1.66
1.86
2.03
0.39
0.71
0.47
Diluted Shares Outstanding
159,343.00
173,110.00
163,554.00
164,192.00
156,257.00
145,669
EBITDA
414,676.00
-
548,968.00
191,467.00
218,818.00
84,136
Non-Operating Interest Income
19,218.00
315.00
-
-
-
-
Minority Interest Expense
-
-
-
53.00
47.00
-
About PDL BioPharma
View Profile
